Washington, October 3, 2021 – “The United States are turning the page from the most recent leap in cases of Covid“He affirms it Anthony Fauci, the American immunologist scientific advisor to the White House, in an interview with CNN. In the interview Fauci defines “impressive” the results of Merck’s anti-Covid pill.
Covid in Italy: the bulletin of October 3
Merck e Ridgeback Botherapeutics they have announced On Friday, the first results indicate that their experimental oral antiviral drug molnupiravir could halve the risk of death or hospitalization from Covid-19.
But when will it arrive authorization of regulatory bodies, such as the Food and Drug Administration? Fauci was not out of balance in forecasts. While the American pharmaceutical giant wasted no time. Based on comforting data from the trial, Merck prepares to apply for a marketing authorization to other regulatory agencies as well worldwide.
Confidence in a successful and rapid process led Merck to get started production of the drug even before obtaining the results of the study, assuming the entire risk: the goal is to produce 10 million doses already by the end of 2021. Furthermore, the company has entered into an agreement with the United States government under which, once the drug is approved, it will provide approximately 1.7 million doses by molnupiravir. Purchase and supply agreements are underway with other governments and the intention is to adopt a differentiated pricing policy based on the World Bank’s income criteria.
However, experts reiterate that the anti Covid pill cannot be alternative to vaccinations, which remain the most effective path to ending the Coronavirus pandemic.
© All rights reserved